Physician profile
Pavel Odintsov
NPI 1073893178
$2,096.86
in general payments reported to CMS, 2019-2025
20 companies · $572 in 2025
The $572 reported for 2025 was more than what 77% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $527 · 2023: $425 · 2024: $417 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,413.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $1,152.80 | 2021-2025 | Ztlido |
| Horizon Therapeutics Plc | $163.51 | 2021-2022 | |
| Lundbeck LLC | $158.41 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $120.87 | 2025 | Auvelity |
| Fidia Pharma USA INC. | $63.54 | 2021-2023 | Triluron, Hymovis |
| Otsuka America Pharmaceutical, INC. | $53.09 | 2024-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $49.49 | 2025 | Trintellix |
| Corium, LLC | $47.89 | 2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $44.30 | 2025 | Qelbree |
| Abbvie INC. | $34.70 | 2025 | |
| Intra-Sana Laboratories | $34.14 | 2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Forte Bio-Pharma LLC | $26.35 | 2024 | Prolate, Nalocet |
| Pfizer INC. | $23.35 | 2025 | |
| Collegium Pharmaceutical, INC. | $19.85 | 2023 | Xtampza |
| Ibsa Pharma INC. | $19.47 | 2023 | Licart, Tirosint |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.64 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $18.27 | 2025 | |
| Merz North America, INC. | $18.21 | 2021 | |
| Tris Pharma INC | $16.25 | 2025 | Dyanavel Xr |
| Kowa Pharmaceuticals America, INC. | $13.73 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavel Odintsov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.